Hayfin is pleased to announce that it has acted as Lead Arranger and Agent to global skincare company Crown Laboratories to support its acquisition of Revance Therapeutics (“Revance”; NSDQ; RVNC) with an $850 million first and second lien credit facility.

Hayfin has been a financing partner to Crown Laboratories since 2015, supporting the business both before and during Hildred Capital’s current ownership period. Since then, Hayfin has completed multiple acquisition financings and refinancings in support of Crown Laboratories as the business has scaled.

The acquisition of Revance enables Crown Laboratories to further bolster its best-in-class portfolio and aesthetic skincare products with DAXXIFY and the RHA collection of dermal fillers. As a biotechnology company, Revance will help complement Crown’s existing product portfolio through its innovative aesthetic and therapeutic offerings, enhancing patient outcomes and physician experiences.

Barrett Polan, Managing Director at Hayfin, said: “We are excited to continue our support of long-standing clients, Hildred Capital and Crown Laboratories, as they enter a new and exciting chapter in the Crown Laboratories story with this acquisition. The firm has been on an exceptional growth journey over the past years and has cemented its reputation as one of the foremost providers of aesthetic solutions. The combined portfolio of Crown Laboratories and Revance will enable them to capitalise on future commercial opportunities to grow and we look forward to supporting them on this journey in the future.”

Hayfin invests in the healthcare sector across its private credit strategies and through its specialist healthcare team, which focuses on making strategic investments throughout the capital structure from Hayfin’s various private credit strategies.